{"nctId":"NCT00471497","briefTitle":"A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","startDateStruct":{"date":"2007-07-31","type":"ACTUAL"},"conditions":["Myelogenous Leukemia, Chronic"],"count":846,"armGroups":[{"label":"nilotinib 300mg bid (investigating arm)","type":"EXPERIMENTAL","interventionNames":["Drug: nilotinib"]},{"label":"Nilotinb 400 mg bid (investigating arm)","type":"EXPERIMENTAL","interventionNames":["Drug: nilotinib"]},{"label":"imatinib 400mg QD (control arm)","type":"EXPERIMENTAL","interventionNames":["Drug: imatinib"]}],"interventions":[{"name":"nilotinib","otherNames":["AMN107"]},{"name":"imatinib","otherNames":["STI571"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion criteria:\n\n* Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.\n* Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome of (9:22) translocations\n\nKey Exclusion criteria:\n\n* Previously documented T315I mutation\n* Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except for no more than 2 weeks in duration of imatinib\n* Any medical treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide\n* Impaired cardiac function.\n* Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).\n* Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)\n* Currently receiving treatment with any medications that have the potential to prolong the QT interval.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation","description":"MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"44.3","spread":null},{"groupId":"OG002","value":"42.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With Imputation","description":"MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":null},{"groupId":"OG001","value":"40.8","spread":null},{"groupId":"OG002","value":"53.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null},{"groupId":"OG001","value":"50.5","spread":null},{"groupId":"OG002","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"41.0","spread":null},{"groupId":"OG002","value":"32.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Rates of Durable MMR at 24 Months Between All 3 Arms","description":"Durable MMR at 24 months is defined as having MMR both at 12 months and at 24 months, and with no documented loss of MMR between these 12 month and 24 month time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null},{"groupId":"OG001","value":"41.8","spread":null},{"groupId":"OG002","value":"39.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months and Beyond 12 Months","description":"CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Patients with no CCyR as the best response by any specific time point, all missing cytogenetic evaluations by that time point or Ph- at baseline are combined as \"Nocomplete cytogenetic response\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"70.2","spread":null},{"groupId":"OG002","value":"68.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"66.0","spread":null},{"groupId":"OG002","value":"66.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"9.2","spread":null},{"groupId":"OG002","value":"12.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"8.9","spread":null},{"groupId":"OG002","value":"13.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"1.8","spread":null},{"groupId":"OG002","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms","description":"MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months based on 12-month cut-off interim data.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":null},{"groupId":"OG001","value":"42.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of MMR at 6 Months and Beyond in All 3 Treatment Arms","description":"MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"33.0","spread":null},{"groupId":"OG002","value":"29.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"44.7","spread":null},{"groupId":"OG002","value":"43.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"61.7","spread":null},{"groupId":"OG002","value":"59.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":null},{"groupId":"OG001","value":"59.2","spread":null},{"groupId":"OG002","value":"57.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"59.9","spread":null},{"groupId":"OG002","value":"55.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"62.8","spread":null},{"groupId":"OG002","value":"61.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"52.5","spread":null},{"groupId":"OG002","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"50.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"46.1","spread":null},{"groupId":"OG002","value":"46.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"43.3","spread":null},{"groupId":"OG002","value":"40.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null},{"groupId":"OG001","value":"37.9","spread":null},{"groupId":"OG002","value":"39.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib","description":"Molecular response of \\<=0.01% is defined as BCR-ABL ratio (%) on IS \\<= 0.01% (corresponds to \\>=4 log reduction of BCR-ABL transcripts from standardized baseline value)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"8.9","spread":null},{"groupId":"OG002","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"12.1","spread":null},{"groupId":"OG002","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"24.5","spread":null},{"groupId":"OG002","value":"22.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"29.4","spread":null},{"groupId":"OG002","value":"23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null},{"groupId":"OG001","value":"33.0","spread":null},{"groupId":"OG002","value":"29.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":null},{"groupId":"OG001","value":"47.9","spread":null},{"groupId":"OG002","value":"43.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null},{"groupId":"OG001","value":"44.3","spread":null},{"groupId":"OG002","value":"45.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":null},{"groupId":"OG001","value":"42.9","spread":null},{"groupId":"OG002","value":"40.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"39.7","spread":null},{"groupId":"OG002","value":"38.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.2","spread":null},{"groupId":"OG001","value":"40.4","spread":null},{"groupId":"OG002","value":"34.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"35.5","spread":null},{"groupId":"OG002","value":"33.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of a ≥ 4.5 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib","description":"This is the molecular response of \\<=0.0032% is defined as BCR-ABL ratio (%) on IS \\<= 0.0032% (corresponds to \\>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"3.5","spread":null},{"groupId":"OG002","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"4.6","spread":null},{"groupId":"OG002","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"12.4","spread":null},{"groupId":"OG002","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"13.8","spread":null},{"groupId":"OG002","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"16.3","spread":null},{"groupId":"OG002","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null},{"groupId":"OG001","value":"32.3","spread":null},{"groupId":"OG002","value":"29.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"31.2","spread":null},{"groupId":"OG002","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"31.6","spread":null},{"groupId":"OG002","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"31.9","spread":null},{"groupId":"OG002","value":"32.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"31.9","spread":null},{"groupId":"OG002","value":"28.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"27.0","spread":null},{"groupId":"OG002","value":"25.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First MMR","description":"Time to MMR is defined as time from date of randomization to the date of the first documented MMR in nilotinib treatment arms, compared to imatinib in adult patients with Ph+ CML in CP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.13","spread":null},{"groupId":"OG001","value":"8.31","spread":null},{"groupId":"OG002","value":"8.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of MMR","description":"Duration of MMR for patients with MMR is defined as the time between date of MMR and the earliest of the following: loss of MMR, CML-related death or progression to AP/BC during study treatment The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts","description":"Time to BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% is defined as: date of first BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% - date of randomization +1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.46","spread":null},{"groupId":"OG001","value":"19.38","spread":null},{"groupId":"OG002","value":"22.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.29","spread":null},{"groupId":"OG001","value":"32.46","spread":null},{"groupId":"OG002","value":"35.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts","description":"It is defined as the time from the date of first documented BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% to the earliest of the following: Loss of BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032%, respectively, CML-related death or progression to AP/BC during study treatment. The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Hematologic Response","description":"Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \\<10 x 109/L, Platelet count \\<450 x 109/L, Basophils \\<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \\< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null},{"groupId":"OG001","value":"90.1","spread":null},{"groupId":"OG002","value":"89.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null},{"groupId":"OG001","value":"90.8","spread":null},{"groupId":"OG002","value":"90.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null},{"groupId":"OG001","value":"92.2","spread":null},{"groupId":"OG002","value":"90.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Complete Cytogenic Response (CCyR)","description":"Time to CCyR is defined as the time from the date of randomization to the date of first documented CCyR","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"5.7","spread":null},{"groupId":"OG002","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of CCyR","description":"Duration of CCyR is defined as the time from date of first documented CCyR to the earliest date of loss of CCyR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Progression-free survival is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring in the core or extension study, or during the follow-up period after discontinuation of core or extension study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival (EFS)","description":"Event-free survival is defined as the time from the date of randomization to the date of first occurrence of any of the following: death due to any cause (if death is the primary reason for discontinuation), progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from the date of randomization to the date death. Up to 10 calendar years of follow up from the date when the last patient randomized received the first dose of study drug in all active treatment arms of adult patients with Ph+ CML CP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Actual Dose-intensity","description":"Actual dose intensity is defined as total dose over time on treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"400.0","spread":null},{"groupId":"OG001","value":"591.1","spread":null},{"groupId":"OG002","value":"758.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression to AP/BC","description":"Time to progression to AP/BC is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of CML related death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Cmax","description":"Cmax is defined as the maximum serum concentration after dose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1555","spread":null},{"groupId":"OG001","value":"1440","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Cmin","description":"Cmin is defined as the minimum serum concentration after dose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1430","spread":null},{"groupId":"OG001","value":"915","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Tmax","description":"Tmax is defined as the sampling time when maximum measured serum concentration occurs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":null},{"groupId":"OG001","value":"1.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: AUC0-last","description":"AUC0-last is defined as area under concentration-time curve from time zero to the last measurable sample, calculated by log-linear trapezoidal method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14446","spread":null},{"groupId":"OG001","value":"11689","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)","description":"Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \\<10 x 109/L, Platelet count \\<450 x 109/L, Basophils \\<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \\< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"84.6","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)","description":"Rate of CCyR is defined as the percentage of participants in complete cytogenetic response (CCyR). CcyR is defined as 0% of Ph+ metaphases in the bone marrow.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"73.1","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)","description":"Rate of MMR is defined as the percentage pf participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR))","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":null},{"groupId":"OG001","value":"73.1","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)","description":"Molecular response of \\<=0.01% is defined as BCR-ABL ratio (%) on IS \\<= 0.01% (corresponds to \\>=4 log reduction of BCR-ABL transcripts from standardized baseline value)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"57.7","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)","description":"Molecular response of \\<=0.0032% is defined as BCR-ABL ratio (%) on IS \\<= 0.0032% (corresponds to \\>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"38.5","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension)","description":"This is the percentage of patients with any emergent mutation on extension treatment. The mutation comprised of T315T, less sensitive to nilotinib, unknown and sensitive to nilotinib.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"11.5","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"On treatment deaths were collected from first patient first visit up to 28 days after study treatment discontinuation (approx. 11 years). Patients with cancer were also followed up for overall survival until the end of the trial (to collect any deaths occurring more than 28 days after study drug discontinuation). In this study, one death was collected after randomization but before the participant received study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":96,"n":280},"commonTop":["Rash","Headache","Nausea","Diarrhoea","Nasopharyngitis"]}}}